Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alprazolam
Drug ID BADD_D00085
Description Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]
Indications and Usage Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults.[L34783] Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.[L34783, L34788] Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.[A177973]
Marketing Status approved; illicit; investigational
ATC Code N05BA12
DrugBank ID DB00404
KEGG ID D00225
MeSH ID D000525
PubChem ID 2118
TTD Drug ID D0L9GG
NDC Product Code 72789-151; 49452-0295; 0009-0055; 45865-972; 49884-213; 0228-2039; 0228-3084; 53002-3952; 59762-3719; 60760-550; 63187-966; 68071-2220; 68071-5243; 68788-7595; 70518-2870; 70518-3763; 71335-1386; 71335-1669; 71335-9666; 71335-9667; 71610-696; 72189-213; 0228-2031; 65862-678; 49884-110; 51991-706; 0228-3086; 53002-0340; 59762-0066; 59762-3722; 60760-678; 65862-677; 67296-1748; 68071-2976; 68788-7596; 0054-3068; 71205-652; 71335-0849; 71335-1576; 71335-1839; 72189-240; 72789-313; 0781-1079; 80425-0110; 42816-0055; 42816-0094; 65862-454; 65862-457; 71554-013; 59762-0057; 61919-005; 63187-444; 63187-445; 63187-916; 65162-813; 68071-2965; 71205-284; 71205-718; 71335-1907; 65162-810; 71335-1291; 71610-112; 0615-8295; 0228-2029; 12780-4630; 64330-013; 0009-0068; 49884-214; 50090-2819; 50090-5258; 0228-2027; 51991-705; 51991-707; 59762-3721; 65862-676; 67296-0757; 67544-414; 68071-2236; 68071-2794; 70518-3259; 70954-510; 71205-614; 71335-1894; 72189-121; 72189-450; 0781-1061; 12828-0040; 42816-0029; 42816-0057; 0009-0057; 0009-0059; 43063-609; 45865-424; 50090-5262; 0228-4019; 0228-4022; 55700-929; 59762-0059; 59762-3720; 63187-443; 65862-456; 68071-2292; 68071-4831; 70954-509; 70954-511; 71205-227; 71335-1477; 80425-0161; 0009-5144; 42816-0090; 65015-634; 65862-679; 0009-0066; 50090-5078; 51991-704; 0228-3083; 67544-415; 68071-5263; 68788-8410; 70518-2785; 70518-3730; 0781-1077; 80425-0099; 80425-0100; 80425-0284; 42816-0059; 42816-0066; 42816-0068; 63187-518; 68071-5113; 68071-5128; 68788-7613; 68788-9682; 71335-1092; 71610-113; 72789-042; 83008-010; 65862-455; 0009-0029; 0009-0090; 45865-993; 49884-111; 0228-4024; 63187-971; 65162-809; 65162-812; 68788-7594; 68788-8394; 71335-2133; 71335-9660; 49999-252; 50090-2896; 50090-5261; 63187-225; 67544-347; 68071-2966; 68788-8414; 70954-508; 71335-0427; 71335-0920; 71335-1129; 72162-1059; 72789-024; 72789-328; 0781-1089; 57218-312; 0009-0094; 0228-3087; 0228-4025; 53002-4181; 55289-523; 59762-0068
UNII YU55MQ3IZY
Synonyms Alprazolam | Alprazolan | Trankimazin | U-31,889 | U31,889 | Xanax | Alprox | Esparon | Cassadan | D-65MT | D65MT | Kalma | Novo-Alprazol | Novo Alprazol | Nu-Alpraz | Nu Alpraz | Ralozam | Tafil | Apo-Alpraz | Apo Alpraz
Chemical Information
Molecular Formula C17H13ClN4
CAS Registry Number 28981-97-7
SMILES CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Brain oedema12.01.10.010; 17.07.02.0030.000082%
Brain death17.02.03.003; 08.04.01.0040.000091%Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.000233%Not Available
Homicidal ideation19.05.01.0080.000078%Not Available
Left ventricular dysfunction02.04.02.0110.000068%
Basophil count13.01.06.042--Not Available
Left ventricular hypertrophy02.04.02.0140.000029%Not Available
Muscle tightness15.05.03.0070.000039%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000266%Not Available
Impatience19.05.01.0140.000029%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.000767%Not Available
Abulia19.01.02.009; 17.02.05.0400.000019%Not Available
Dysstasia08.01.03.089; 17.02.02.012; 15.03.05.0110.000049%Not Available
Subileus07.13.01.0040.000039%Not Available
Self-injurious ideation19.12.01.0070.000029%Not Available
Tonic clonic movements17.12.03.0060.000049%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000078%Not Available
Sticky skin23.03.03.019--Not Available
Haemodynamic instability24.03.02.0060.000029%Not Available
Ear discomfort04.03.01.0050.000043%Not Available
Paranasal sinus discomfort22.12.03.0180.000066%Not Available
Drug tolerance08.06.01.0030.000200%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Epigastric discomfort07.01.02.0040.000019%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Organ failure08.01.03.0410.000019%Not Available
Alcohol withdrawal syndrome08.06.02.002; 19.07.06.0050.000058%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000049%Not Available
Depressive symptom19.15.02.0030.000039%Not Available
Affect lability19.04.01.001--Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene